QUEST informs readers of the latest advances in urologic prostate cancer research, especially detection, prevention, and treatment.
Intermittent Hormonal Therapy is a new, experimental treatment option for prostate cancer. Previous Use of Hormonal Therapy Hormonal therapy is usually effective in the treatment of prostate cancer, especially for patients who have had recurrence of their cancer after surgery…
The following article contains a good deal of technical information, but we feel the information is helpful and would be of interest to many of our QUEST readers. Hormonal therapy is most often used after both a radical prostatectomy and…
Postoperative radiation therapy is for patients who have a rising PSA after radical prostatectomy or have adverse findings in their radical prostatectomy pathology report. These adverse findings are extra-prostatic tumor extension, cancer cells at the surgical margins, seminal vesicle invasion,…
A relatively new and helpful addition in the diagnosis of prostate cancer is the free PSA Test. This blood test is done in addition to the PSA Test and the finger (digital) examination. The PSA Test measures a protein in…
It is easy to tell a patient that his tumor is potentially life-threatening if there is a lot of cancer found in the biopsy specimens, the Gleason score is 7 or higher, or if the PSA level has been persistently…
Open nerve-sparing radical retropubic prostatectomy (RRP) is the gold standard for the surgical treatment of prostate cancer. For patients, the most important outcomes are: Am I cured of my cancer? Am I continent? Can I have erections sufficient for intercourse?…
Jim Boeheim’s attitude toward statistics tells a lot about how he treated his diagnosis of prostate cancer when he was 56. He readily knows how many wins he’s been part of as basketball coach at Syracuse University – 829. Ask…
Blood loss during any operation can affect the surgeon’s view of and access to the area of concern. It can also affect the recovery time and general “well being” of the patient. A better understanding of the male pelvic blood…
In 2010, the National Comprehensive Cancer Network (NCCN) published revised guidelines for prostate cancer screening. Two of the recommendations are: to perform annual screening for men in ther 40’s with a baseline PSA level greater than 1 and to consider…
Cabaztaxel is a new chemotherapy for prostate cancer recently approved by the FDA. A recent multicenter phase 3 clinical trial showed that cabazitaxel (Jevtana® Injection, Sanofi-Aventis) prolongs survival among patients with castrationresistant prostate cancer whose cancer also progressed following treatment…
"*" indicates required fields
